Difference in blood pressure response to ACE-Inhibitor monotherapy between black and white adults with arterial hypertension: a meta-analysis of 13 clinical trials. by Peck, Robert N et al.
Peck, RN; Smart, LR; Beier, R; Liwa, AC; Grosskurth, H; Fitzger-
ald, DW; Schmidt, BM (2013) Difference in blood pressure response
to ACE-Inhibitor monotherapy between black and white adults with
arterial hypertension: a meta-analysis of 13 clinical trials. BMC
Nephrol, 14 (1). p. 201. ISSN 1471-2369
Downloaded from: http://researchonline.lshtm.ac.uk/1236369/
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution http://creativecommons.org/licenses/by/2.5/
RESEARCH ARTICLE Open Access
Difference in blood pressure response to
ACE-Inhibitor monotherapy between black and
white adults with arterial hypertension:
a meta-analysis of 13 clinical trials
Robert N Peck1,2,3*, Luke R Smart1,2,3, Rita Beier4, Anthony C Liwa5, Heiner Grosskurth6, Daniel W Fitzgerald3
and Bernhard MW Schmidt7
Abstract
Background: Among African-Americans adults, arterial hypertension is both more prevalent and associated with
more complications than among white adults. Hypertension is also epidemic among black adults in sub-Saharan
Africa. The treatment of hypertension among black adults may be complicated by lesser response to certain classes
of anti-hypertensive agents.
Methods: We systematically searched literature for clinical trials of ACE-inhibitors among hypertensive adults
comparing blood pressure response between whites and blacks. Meta-analysis was performed to determine the
difference in systolic and diastolic blood pressure response. Further analysis including meta-regressions, funnel
plots, and one-study-removed analyses were performed to investigate possible sources of heterogeneity or bias.
Results: In a meta-analysis of 13 trials providing 17 different patient groups for evaluation, black race was associated
with a lesser reduction in systolic (mean difference: 4.6 mmHg (95% CI 3.5-5.7)) and diastolic (mean difference:
2.8 mmHg (95% CI 2.2-3.5)) blood pressure response to ACE-inhibitors, with little heterogeneity. Meta-regression
revealed only ACE-inhibitor dosage as a significant source of heterogeneity. There was little evidence of publication bias.
Conclusions: Black race is consistently associated with a clinically significant lesser reduction in both systolic and
diastolic blood pressure to ACE-inhibitor therapy in clinical trials in the USA and Europe. In black adults requiring
monotherapy for uncomplicated hypertension, drugs other than ACE-inhibitors may be preferred, though the proven
benefits of ACE-inhibitors in some sub-groups and the large overlap of response between blacks and whites must be
remembered. These data are particularly important for interpretation of clinical drug trials for hypertensive black adults
in sub-Saharan Africa and for the development of treatment recommendations in this population.
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Background
Hypertension is a growing problem among black adults
worldwide. Black adults have the highest age-adjusted
rates of hypertension among all racial groups in the
United States of America (USA) and Europe. Among
black adults in the USA, for example, 44.4% of men and
43.9% of women have hypertension compared to 33.3%
in the general population [1]. Black adults also suffer
from increased adverse consequences of hypertension
due to: 1) more severe hypertension (>180/110 mmHg),
2) less adequate blood pressure control over the long
term, and 3) more comorbid conditions such as diabetes
mellitus and chronic kidney disease [2].
In sub-Saharan Africa, hypertension is epidemic among
black adults. Although previously considered rare [3-6],
the prevalence of hypertension in sub-Saharan Africa is
rising rapidly due to the effects of urbanization and
industrialization on diet, exercise and obesity [3,4,7,8]. In a
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recent large community-based study in Tanzania, for ex-
ample, 21% of black adults between the ages of 35–
44 years had hypertension; of these, only 18% were aware
of their diagnosis, only 14% were on treatment, and only
5% were controlled [8]. Several studies among black adults
in Nigeria and South Africa have consistently reported
that 15-20% of all hospital admissions in Africa are due to
hypertension-related diagnoses [9-12]. Autopsy and death
certificate studies show that a large proportion of in-
hospital deaths are hypertension-related even among
younger adults [13-16].
One frequently cited challenge of treating hyperten-
sion among black adults is the lesser blood pressure re-
sponse to certain medications such as ACE-inhibitors
(ACEI) [17-20]. The objectives of this meta-analysis were
to combine all currently available evidence from clinical
trials of ACEIs to identify the following: 1) if a signifi-
cant difference in blood pressure response to ACEIs ex-
ists between black and non-black populations, 2) the
magnitude of this potential difference and 3) whether
this potential difference may be explainable by factors
other than race.
Methods
We systematically searched PubMed, EMBASE and Web
of Science for any prospective clinical trials providing
race specific data on blood pressure lowering during
treatment with ACEIs for adults with arterial hyperten-
sion on 3 August 2012. The search strategies were cre-
ated by practicing clinicians and a research librarian and
are provided in the Additional file 1: Table S1. No publi-
cation date or publication status restrictions were ap-
plied, and all languages were allowed. In addition,
reference lists of review articles and the selected articles
were searched for additional sources.
Once the systematic literature search was complete,
two independent reviewers appraised all articles
according to a standard set of inclusion and exclusion
criteria. In cases of differing results, a third reviewer ad-
judicated. In the first step, articles were excluded or in-
cluded based on a review of their titles and abstracts.
The remaining articles were then evaluated in full text.
All articles fulfilling the below-mentioned criteria were
selected and data were extracted.
Inclusion/exclusion criteria were as follows. The study
must be a prospective clinical trial providing race spe-
cific data on blood pressure lowering during treatment
with ACEI. Study participants must be aged ≥18 years.
Studies were included only if they enrolled patients for
treatment of confirmed arterial hypertension. In order to
evaluate the pure effect of ACEI therapy itself on blood
pressure reduction, studies that used combination ther-
apy were excluded from the analysis. The minimum
treatment duration was 4 weeks; the minimum patient
number was ten.
Two independent reviewers performed data extraction
in duplicate. In the case of disagreement, a 3rd reviewer
examined the article in order to correct the difference.
Data were all entered into a standardized evidence table
(see Additional file 2: Table S2). The dual primary meta-
meters and measures of variance in this meta-analysis
were change in systolic and diastolic blood pressure in
mmHg and standard deviation from before start of ACEI
treatment to the end of the study period.
The following parameters were also extracted and in-
cluded in the evidence table: number of patients in each
race group, Jadad score (for quality), average age, age dif-
ference between races, gender distribution, ACE-inhibitor
used and average dose, time interval between start of
treatment and blood pressure measurement. Of note, the
Jadad score is a standard measure of the quality of clinical
trials ranging from 0 (low quality) to 5 (high quality) that
takes into account the following components: randomi-
zation, blinding, and loss to follow-up [21]. ACE-inhibitor
doses were standardized as “enalapril adjusted doses”. The
doses of fosinopril, quinapril, benazepril and lisinopril
were identical to those of enalapril; the trandolapril dose
was multiplied by 10; the ramipril dose was multiplied by
4; perindopril doses of 2, 4, 6, and 8 mg and captopril daily
doses of 18.75, 37.5, 75, and 150 mg were equivalent to
enalapril doses of 5, 10, 20, and 40 mg.
For one study, two references were used for data ex-
traction [22,23]. For that study, the authors were
contacted in order to get the standard deviations of the
mean blood pressures. ImageJ (free share software, NIH,
USA) was used in two articles to obtain measures of
mean and standard deviation from a graph.
The meta-analysis was performed using random ef-
fects model. Mean difference and 95% confidence inter-
vals (95% CI) were calculated. We tested for heterogeneity
by Q test and I2 statistics. We assessed possibility of publi-
cation bias by evaluating a funnel plot for asymmetry and
by Egger’s regression intercept. To evaluate the possible
sources of heterogeneity we performed metaregression
and stratification according to the above-mentioned fac-
tors. As two studies in the meta-analysis had a much lar-
ger sample sizes than the other studies, we performed a
one-study-removed analysis to assess whether the re-
moval of any one study changed the overall results of the
meta-analysis.
We hypothesized that black race was associated with a
lesser reduction in systolic and diastolic blood pressure
in response to ACE-inhibitor therapy. We also hypothe-
sized that possible sources of heterogeneity between
studies could include: age, ACE-inhibitor dose, study
quality (i.e. Jadad score), treatment duration and/or
baseline blood pressure.
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Results
Our systematic literature search revealed 909 articles:
252 from PubMed, 137 from Embase and 520 from Web
of Science. After removal of duplicates, 795 articles were
reviewed on the basis of the title and the abstract. This
led to the removal of 734 articles. The 61 remaining arti-
cles were examined in full text. Of these, 14 fulfilled the
inclusion/exclusion criteria. These 14 articles reported
13 different studies and provided 17 different patient
groups for evaluation [22-35]. The main reasons for ex-
clusion are described in Figure 1.
Table 1 shows the characteristics of the 13 clinical trials
included in our meta-analysis. Studies recruited between
25 and 8887 patients and were conducted between 1982
and 2009. All but one [34], were conducted in the USA.
The mean age ranged from 47.5 to 66 years and was
typical for hypertensive cohorts. A large variety of ACEIs
across the recommended dose range were used. See
Additional file 2: Table S2 for details regarding study
designs and type of ACEI. Table 2 shows the findings of
these 13 clinical trials.
Data on systolic blood pressure changes were available
from 15 patient groups out of 11 studies. In the pooled
analysis, white race was associated with a greater reduction
in systolic blood pressure (mean difference 4.64 mmHg
(95% CI 3.53 - 5.75)). We detected little heterogeneity
within this comparison. The I2 statistic was 24.2 and the
Q test was not statistically significant (p = 0.19). The For-
est Plot for difference in mean change in systolic blood
pressure between whites and blacks is displayed in
Figure 2.
Data on diastolic blood pressure changes were available
from 16 patient groups out of 12 studies. In the pooled
analysis, white race was associated with a greater reduction
in diastolic blood pressure (mean difference 2.82 mmHg
(95% CI 2.17 – 3.47)). We detected some heterogeneity
within this comparison. The I2 statistic was 59.0 and the
Q test was statistically significant (p < 0.0001). The Forest
909 records identified through 
database searching
0 records identified through other 
sources
114 duplicates removed
795 records screened after removal of duplicates
734 records excluded by abstract and title review
292 reviews, editorials, guidelines
183 observational studies
76 no race specific data
53 population not hypertensive
39 combination therapy
35 not treated with ace -i
15 N in study < 10
14 no blood pressure reduction provided
11 cellular/animal subjects
8 pediatric subjects
8 follow-up < 4 weeks
61 full-text articles assessed for eli gibility
47 articles excluded by full -text review
21 no race specific data
6 reviews, editorials, guidelines
5 population not hypertensive
4 combination therapy
4 no precision recorded
2 N in study < 10
2 not treated with ace -i
1 observational studies
1 pediatric subjects
1 follow-up < 4 weeks
14 articles (13 studies)
included in qualitative synthesis
14 articles (13 studies)
included in quantitative synthesis
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Figure 1 Flow diagram for identification, screening, and inclusion of papers for this meta-analysis.
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Table 1 Characteristics of the 13 clinical trials (17 patient groups) included in this meta-analysis
N of subjects Age of subjects (years) Duration
(weeks)
Jadad
score
Mean baseline blood pressure
systolic/diastolic (mm Hg)
White Black White Black White Black
1 Study Group 1982 [26] 170 151 55 7 3 148.2/97.4 147.6/97.8
2 Weinberger 1985 [27] 32 37 * * 6 0 149.5/99.6 152.7/99.2
3 Thind 1988 [28] 15 10 47.5 4 0 */97 */101
4a Materson 1993, young [29] 39 44 51 49 4 5 149/99 147/100
4b Materson 1993, old [29] 55 48 66 4 5 154/98 157/100
5a Weir 1995, 1 mg [24] 51 23 58.3 52.7 6 5 154.8/100.3 149.6/100.2
5b Weir 1995, 2 mg [24] 53 22 57.3 53.0 6 5 151.9/101.7 144.8/100.2
5c Weir 1995, 4 mg [24] 53 23 53.0 53.2 6 5 147.6/99.9 155.9/102.9
6 Chrysant 1996 [30] 30 10 53.7 6 4 * *
7 Weir 1998a [32] 32 13 51 12 5 145.6/89 145.8/91.2
8a Weir 1998b, 20 mg [31] 48 22 55.5 51.2 4 3 159.9/103 156/105.8
8b Weir 1998b, 40 mg [31] 43 19 55.6 51.2 4 3 158.4/102.7 157.1/104.8
9 Pahor 2002 [25] 15 18 59.5 4 5 140/86 144/86
10 Cohn 2004 [23], Julius 2004 [22] 7745 1412 56.8 52.3 12 1 157/94.1 156.3/96.5
11 Mokwe 2004 [33] 2046 533 48.9 51.9 18 0 152.2/94.9 150.9/95.6
12 Moran 2007 [35] 89 72 53.8 54.0 8 1 147/87 151/88
13 Van Rijn-Bikker 2009 [34] 33 48 48 6 3 153/95 156/99
*Results not reported.
Table 2 Findings from the 13 clinical trials (17 patient groups) included in this meta-analysis
Decrement in blood pressure with drug treatment (mm Hg)
Systolic Diastolic
Trial Standardized mean
dose (mg/d)
White
mean
Black
mean
White-black
difference
White SD Black SD White
mean
Black
mean
White-black
difference
White SD Black SD
1 20 14.7 9.1 5.6 15.6 14.7 10.7 7.9 2.8 7.8 8.6
2 20 10.8 0.7 10.1 16.4 3.6 9 4.1 4.9 9.1 11.6
3 5 * * * * * 8 1.5 6.5 15.1 11.7
4a 16 11 8 3 9 11 10 9 1 7 7
4b 16 11 7 4 9 12 11 7 4 5 7
5a 10 12.8 2.7 10.1 15 13.9 6.1 2 4.1 4.3 4.8
5b 20 9.6 2.5 7.1 15 13.1 8.1 3.8 4.3 5.1 5.2
5c 40 9.1 11.9 −2.8 13.8 13.4 8.9 6.5 2.4 4.4 5.3
6 20 * * * * * 11.8 6.2 5.6 7.8 10
7 24 14.1 7.8 6.3 10.2 14.4 10.2 6.2 4 6.2 11.5
8a 20 13.4 8.5 4.9 16.3 12.9 9.8 7.3 2.5 8.1 7.5
8b 40 16.8 12.3 4.5 18.5 20 12 10.1 1.9 8.5 11.3
9 30 5.9 9.2 −3.3 13.7 11.9 2.2 3.1 - 0.9 8.1 11.7
10 18 18.2 14.3 3.9 16.3 17.3 10.6 9 1.6 9.6 10.5
11 * 15.3 10.6 4.7 12.2 13.4 9.8 7.4 2.4 7.8 7.8
12 40 11 5 6 14.2 15.3 7 3 4 7.8 8.7
13 15 9.5 0.9 8.6 15.8 19.9 * * * * *
SD indicates standard deviation. *Results not reported.
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Plot for difference in mean change in diastolic blood pres-
sure between whites and blacks is displayed in Figure 3.
In order to detect potential publication or reporting
bias, we performed a separate Funnel Plot analysis for sys-
tolic and diastolic blood pressure. Figure 4 shows the
Funnel Plots, which did not suggest relevant publication
bias. The Eggers Statistics supported this conclusion for
the systolic blood pressure (p = .33), whereas it was statis-
tically significant for diastolic blood pressure (p = 0.01).
We performed meta-regression analysis of age, ACEI
dosage, duration of therapy, Jadad score and baseline
blood pressure with regard to systolic (Figure 5A) and
diastolic (Figure 5B) blood pressure changes. For systolic
blood pressure, use of higher doses of ACEIs was associ-
ated with a statistically significant lesser difference in
mean blood pressure reduction between whites and blacks
(p = 0.048). There was also a trend toward the same find-
ing in diastolic blood pressure but this was not statistically
Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
VA Study Group 1982 -5,600 1,698 2,883 -8,928 -2,272 -3,298 0,001
Weinberger 1985 -10,100 2,768 7,660 -15,525 -4,675 -3,649 0,000
Materson 1993, young -3,000 2,224 4,945 -7,358 1,358 -1,349 0,177
Materson 1993, old -4,000 2,075 4,304 -8,066 0,066 -1,928 0,054
Weir 1995, 1mg -10,100 3,685 13,582 -17,323 -2,877 -2,741 0,006
Weir 1995, 2mg -7,100 3,672 13,485 -14,297 0,097 -1,933 0,053
Weir 1995, 4mg 2,800 3,416 11,672 -3,896 9,496 0,820 0,412
Weir 1998a -6,300 3,791 14,373 -13,731 1,131 -1,662 0,097
Weir 1998b, 20mg -4,900 3,947 15,580 -12,636 2,836 -1,241 0,214
Weir 1998b, 40mg -4,500 5,224 27,287 -14,738 5,738 -0,861 0,389
Pahor 2002 3,300 4,455 19,851 -5,433 12,033 0,741 0,459
Mokwe 2004 -4,700 0,606 0,367 -5,887 -3,513 -7,758 0,000
Cohn 2004, Julius 2004 -3,900 0,521 0,271 -4,921 -2,879 -7,488 0,000
Moran, 2007 -6,000 2,332 5,439 -10,571 -1,429 -2,573 0,010
Van Rijn-Bikker 2009 -8,600 4,157 17,281 -16,748 -0,452 -2,069 0,039
-4,640 0,564 0,319 -5,746 -3,534 -8,221 0,000
-15,00 -7,50 0,00 7,50 15,00
SBP lower in whites SBP lower in blacks
Figure 2 Forest Plot for difference in mean reduction of systolic blood pressure (SBP). Forest Plot for difference in mean reduction of
systolic blood pressure (SBP) between whites and blacks. White race was associated with a greater reduction in SBP (mean difference: 4.64
(95% CI 3.53-5.75)).
Study name Statistics for each study Difference in means and 95% CI
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
VA Study Group 1982 -2,800 0,790 0,625 -4,349 -1,251 -3,543 0,000
Weinberger 1985 -4,900 2,318 5,372 -9,443 -0,357 -2,114 0,035
Thind 1988 -6,500 4,264 18,182 -14,857 1,857 -1,524 0,127
Materson 1993, young -1,000 1,359 1,847 -3,664 1,664 -0,736 0,462
Materson 1993, old -4,000 1,065 1,135 -6,088 -1,912 -3,755 0,000
Chrysant 1995 -5,590 2,204 4,859 -9,910 -1,270 -2,536 0,011
Weir 1995, 1mg -4,100 0,838 0,702 -5,742 -2,458 -4,894 0,000
Weir 1995, 2mg -4,300 0,926 0,857 -6,114 -2,486 -4,645 0,000
Weir 1995, 4mg -2,400 0,886 0,785 -4,137 -0,663 -2,709 0,007
Weir 1998a -4,000 2,236 4,998 -8,382 0,382 -1,789 0,074
Weir 1998b, 20mg -2,500 1,452 2,109 -5,346 0,346 -1,722 0,085
Weir 1998b, 40mg -1,900 2,034 4,139 -5,887 2,087 -0,934 0,350
Pahor  2002 0,900 3,138 9,846 -5,250 7,050 0,287 0,774
Mokwe 2004 -2,400 0,231 0,053 -2,853 -1,947 -10,393 0,000
Cohn 2004, Julius 2004 -1,600 0,157 0,025 -1,907 -1,293 -10,200 0,000
Moran, 2007 -4,000 1,302 1,694 -6,551 -1,449 -3,073 0,002
-2,821 0,330 0,109 -3,467 -2,174 -8,550 0,000
-15,00 -7,50 0,00 7,50 15,00
DBP lower in whites DBP lower in blacks
Figure 3 Forest Plot for difference in mean reduction of systolic blood pressure (SBP). Forest Plot for difference in mean reduction of
diastolic blood pressure (DBP) between whites and blacks. White race was associated with a greater reduction in DBP (mean difference: 2.82
(95%CI 2.17-3.47)).
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significant. None of the other meta-regressions were sta-
tistically significant and most other meta-regression vari-
ables trended toward even greater difference in mean
reduction in blood pressure with greater age, duration of
treatment, study quality, and baseline blood pressure.
As two studies in the meta-analysis had much larger
sample sizes than the other studies, we performed a
one-study-removed analysis to assess whether the re-
moval of any one study changed the overall results of
the meta-analysis (Figure 6). No change was observed.
Discussion
In this meta-analysis of 13 unique clinical trials of ACEI
therapy for hypertensive adults providing race-stratified
systolic and/or diastolic blood pressure results, black
race was associated with a consistently lesser response in
both systolic and diastolic blood pressure after ACEI
therapy (4.6 and 2.8 mmHg respectively). The observed
differences in blood pressure response are not only
statistically significant but also clinically important since
a reduction of 4–5 mmHg in SBP and 2–3 mmHg in
DBP has been associated with a 8-20% reduction in risk
of cardiovascular morbidity and mortality [36]. This dif-
ference in BP response is also similar to the hypotensive
effect of some classes of anti-hypertensive agents such
as beta-blockers [37]. These results provide evidence for
recent recommendations that ACEI should not preferred
for monotherapy in black adults with uncomplicated
hypertension [2,19], and that calcium channel blockers
and thiazide diuretics may be a better choice [38]. These
data have particularly important public health implica-
tions for black adults with hypertension in sub-Saharan
Africa where hypertension is epidemic and guidelines
for the treatment of hypertension must consider cost,
availability and population-level, average blood pressure
responses [3,4,7,8].
The difference in blood pressure response to ACEI
monotherapy between blacks and whites observed in this
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Figure 4 Funnel Plots for standard error of changes in systolic (A) and diastolic (B) blood pressure. Funnel Plots for standard error of
difference in mean change in systolic (A) and diastolic (B) blood pressures. These Funnel Plots do not show any evidence of publication bias.
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Figure 5 Meta-regression analyses for systolic (A) and diastolic (B) blood pressure. (A) Meta-regression analyses for systolic blood pressure
(SBP). The difference in SBP reduction between whites and blacks was significantly blunted by increasing doses of ACE inhibitors (p = 0.048).
None of the other associations were statistically significant. Meta-regression analyses for diastolic blood pressure (DBP). (B) Meta-regression
analyses for diastolic blood pressure (DBP). None of the associations were statistically significant but there was a trend toward lesser difference in
DBP reduction between whites and blacks when greater doses of ACE-inhibitors were used.
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meta-analysis appears to be related to race and is not en-
tirely explainable by other factors. One-study-removed
analysis and funnel plots showed no evidence of
overinfluence by a single study or of publication bias.
We also performed careful metaregression to estimate
the impact of possible confounders such as age, baseline
blood pressure, duration of treatment, study quality and
ACEI dose. Of these factors, only ACEI dose had some
mitigating effect on the difference in blood pressure re-
sponse. Higher doses of ACEI may be beneficial among
black adults who require ACEI therapy for hypertension
although higher doses may be associated with more ad-
verse effects. One additional, possible confounder in the
relationship between race and ACE-inhibitor response is
salt intake. Three of the studies included in this meta-
analysis investigated the impact of salt intake on the
Study name Statistics with study removed Difference in means (95% 
CI) with study removedStandard Lower Upper 
Point error Variance limit limit Z-Value p-Value
VA Study Group 1982 -4,572 0,618 0,382 -5,784 -3,360 -7,394 0,000
Weinberger 1985 -4,368 0,442 0,195 -5,233 -3,502 -9,889 0,000
Materson 1993, young -4,764 0,606 0,367 -5,951 -3,577 -7,868 0,000
Materson 1993, old -4,720 0,620 0,384 -5,934 -3,505 -7,616 0,000
Weir 1995, 1mg -4,489 0,526 0,277 -5,520 -3,458 -8,534 0,000
Weir 1995, 2mg -4,596 0,587 0,344 -5,746 -3,446 -7,835 0,000
Weir 1995, 4mg -4,604 0,427 0,182 -5,440 -3,767 -10,790 0,000
Weir 1998a -4,624 0,594 0,353 -5,788 -3,459 -7,783 0,000
Weir 1998b, 20mg -4,662 0,600 0,360 -5,837 -3,486 -7,773 0,000
Weir 1998b, 40mg -4,668 0,596 0,356 -5,837 -3,499 -7,827 0,000
Pahor 2002 -4,668 0,500 0,250 -5,648 -3,689 -9,340 0,000
Mokwe 2004 -4,756 0,775 0,600 -6,274 -3,238 -6,140 0,000
Cohn 2004, Julius 2004 -4,966 0,738 0,545 -6,413 -3,519 -6,727 0,000
Moran, 2007 -4,584 0,602 0,362 -5,763 -3,405 -7,620 0,000
Van Rijn-Bikker 2009 -4,570 0,571 0,326 -5,688 -3,451 -8,009 0,000
-4,640 0,564 0,319 -5,746 -3,534 -8,221 0,000
-15,00 -7,50 0,00 7,50 15,00
SBP lower in whites SBP lower in blacks
Study name Statistics with study removed Difference in means (95% 
CI) with study removedStandard Lower Upper 
Point error Variance limit limit Z-Value p-Value
VA Study Group 1982 -2,835 0,352 0,124 -3,526 -2,145 -8,045 0,000
Weinberger 1985 -2,779 0,331 0,110 -3,428 -2,129 -8,386 0,000
Thind 1988 -2,799 0,331 0,109 -3,447 -2,151 -8,464 0,000
Materson 1993, young -2,915 0,341 0,117 -3,584 -2,246 -8,541 0,000
Materson 1993, old -2,724 0,333 0,111 -3,376 -2,071 -8,182 0,000
Chrysant 1995 -2,752 0,327 0,107 -3,393 -2,112 -8,419 0,000
Weir 1995, 1mg -2,657 0,325 0,105 -3,293 -2,020 -8,181 0,000
Weir 1995, 2mg -2,656 0,323 0,104 -3,288 -2,023 -8,230 0,000
Weir 1995, 4mg -2,875 0,353 0,124 -3,566 -2,184 -8,154 0,000
Weir 1998a -2,800 0,335 0,112 -3,456 -2,144 -8,362 0,000
Weir 1998b, 20mg -2,846 0,342 0,117 -3,517 -2,174 -8,309 0,000
Weir 1998b, 40mg -2,853 0,339 0,115 -3,517 -2,189 -8,418 0,000
Pahor  2002 -2,862 0,332 0,111 -3,513 -2,210 -8,607 0,000
Mokwe 2004 -3,024 0,443 0,196 -3,892 -2,155 -6,823 0,000
Cohn 2004, Julius 2004 -2,990 0,296 0,087 -3,569 -2,411 -10,115 0,000
Moran, 2007 -2,754 0,334 0,112 -3,409 -2,098 -8,233 0,000
-2,821 0,330 0,109 -3,467 -2,174 -8,550 0,000
-15,00 -7,50 0,00 7,50 15,00
DBP lower in whites DBP lower in blacks
Figure 6 One-study-removed analysis for difference in mean reduction of systolic and diastolic blood pressures. One-study-removed
analysis for difference in mean reduction of systolic (SBP, above) and diastolic (DBP, below) blood pressure between whites and blacks. Removal
of each single study did not change the result of the meta-analysis.
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relationship race and ACE-inhibitor with mixed results
[31,34,35]. The most rigorous of these studies de-
monstrated that salt-sensitive black adults had a consist-
ently lesser blood pressure response to ACE-inhibitors
whether the subjects were consuming a high or low salt
diet. It also showed that a low salt diet was associated with
less response to ACEIs among all races [31].
The magnitude of the difference in blood pressure re-
sponse to ACEI therapy observed in this meta-analysis is
quantitatively similar to that observed in other literature.
In the largest randomized, controlled trial that compared
outcomes to ACEI therapy among black and white
adults with hypertension (the ALLHAT study), the dif-
ferences in systolic and diastolic blood pressure response
to lisinopril were 5.6 and 2.5 mmHg respectively [39], al-
most identical to the differences seen in our meta-analysis.
The ALLHAT study was not included in this meta-
analysis, though, because many participants received com-
bination therapy and no data for those patients receiving
monotherapy were extractable from trial publications.
These differences are also similar to the results of 2 prior,
smaller meta-analyses of ACEI response in blacks and
whites [38,40].
It is important to note that the variability of response to
ACEI monotherapy is greater within races than between
races. As seen in Table 2, the standard deviation for blood
pressure responses among whites and blacks was consist-
ently greater than the difference between these 2 groups.
These results affirm the meta-analysis of Sehgal, which
showed that the percentage of whites and blacks with
similar drug-associated changes in diastolic blood pres-
sure was 90% for diuretics, 90% for beta-blockers, 95% for
calcium channel blockers, and 81% for ACEI [40]. Clearly
we are, as races, more similar than we are different.
Both the USA JNC-7 guidelines and the UK NICE
guidelines have noted the difference in in ACEI response
between white and black adults [41,42]. According to
the NICE guidelines, calcium channel blockers are pre-
ferred over ACE-inhibitors for monotherapy of uncom-
plicated hypertension in black adults of any age and in
white adults over the age of 55 years [41]. The cutoff of
55 years is an interesting one. Of the studies included in
this meta-analysis only 1 looked at the difference in
blood pressure response to ACE-inhibitors between
blacks and white in different age groups. In this study,
the systolic and diastolic blood pressure response to
ACEI therapy was similar in younger vs. older whites
and younger vs. older black adults and was consistently
less in younger and older blacks vs. younger and older
whites [29]. The recommendation in the NICE guide-
lines to prefer calcium channel blockers is also notable
and further meta-analysis is needed to better define the
relationship between race and blood pressure response
to calcium channel blockers.
These findings must also be taken in the context of
other clinical trials that have demonstrated the benefit of
ACEI therapy among blacks with certain complications
such as chronic kidney disease and diabetes mellitus
despite lesser reduction in blood pressure [43]. Also, use
of ACEIs as part of a combination for treatment of
hypertension has proven to be effective among black
adults [2]. In fact, according to one meta-analysis,
combination therapy including ACEIs may actually re-
sult in a greater blood pressure reduction in black
adults than white adults [38]. Since black adults are
disproportionately affected by heart and kidney dis-
ease and many will require at least 2 hypertensive
agents for blood pressure control, the use of a com-
bination therapy including an ACE-inhibitor or angio-
tensin receptor blocker may be particularly beneficial
in this population.
This meta-analysis has several important limitations.
First, all of the studies included in this meta-analysis ex-
cept one were done in the USA and therefore may not
be applicable to black adults living in other regions such
as sub-Saharan Africa. Although this is a limitation, we
also believe that this meta-analysis is important in provid-
ing context for the much-anticipated results of the first
large, randomized, controlled trials of antihypertensive
drugs among hypertensive black adults in sub-Saharan
Africa [44]. Also, this meta-analysis was performed on
pooled study results and not individual level data. The
consistency of the difference in mean blood pressure re-
duction, however, does point to a real difference in reduc-
tion by race. Finally, as with any meta-analysis, this study
is limited by the variables that were studied and reported
in the component trials. Since hypertension is multifac-
torial, some important confounders such as nutrition, salt
intake and handling, nephron number or hormone levels
may have been missed.
Conclusion
In conclusion, this study confirms and quantifies the hy-
pothesis that adult black hypertensive patients do gener-
ally have a lesser mean reduction in systolic and
diastolic blood pressure response to ACEI monotherapy
when compared to whites. This meta-analysis provides
evidence for current guidelines that recommend that
drugs other than ACEI should be preferred for uncom-
plicated, mild-moderate hypertension in blacks, guide-
lines that have particular import in sub-Saharan Africa.
These results, though, must be taken in the context of
other research that provides strong evidence for the
benefits of ACEIs in some subgroups of hypertensive
black adults, particularly those with certain complica-
tions such as chronic kidney disease and diabetes
mellitus and those requiring multi-drug therapy for their
hypertension. For hypertensive black adults in whom
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ACEI monotherapy is indicated, higher doses may be
necessary to obtain the desired reduction in blood
pressure.
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